Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov-Dec;6(6):535-545.
doi: 10.22608/APO.2017350. Epub 2017 Oct 26.

Anti-VEGF Therapy for Diabetic Eye Diseases

Bobak Bahrami  1   2 , Thomas Hong  2 , Mark C Gilles  1 , Andrew Chang  1   2
Affiliations
Free article
Review

Anti-VEGF Therapy for Diabetic Eye Diseases

Bobak Bahrami et al. Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec.
Free article

Abstract

Diabetic retinopathy (DR) is a leading cause of vision impairment and blindness in the working-age population. The identification of vascular endothelial growth factor (VEGF) as a key mediator in the pathogenesis of DR has revolutionized the management of this vision-threatening disease. There is now strong evidence supporting intravitreal anti-VEGF therapy as first line in the management of sight-threatening diabetic macular edema (DME), along with a growing body of evidence to support the use of anti-VEGF drugs for proliferative DR. This review summarizes the role of VEGF in DR, the evidence for anti-VEGF therapy, safety considerations, and the future of anti-VEGF therapy for the management of DR.

Keywords: diabetic macular edema; diabetic retinopathy; vascular endothelial growth factor.

PubMed Disclaimer

MeSH terms

Substances